how can i buy digital currency- Top snippets

As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.In addition, the market value of Zhongwei Company, Weir Shares and UIH Medical all exceeded 100 billion yuan.Zhongwei company is a company engaged in the research, development, production and sales of high-end semiconductor equipment and pan-semiconductor equipment. Great Wall Securities said that the company's etching, thin film deposition and MOCVD equipment have reached the international advanced level.

After-hours big profits are related to mergers and acquisitions, restructuring, Shanghai state-owned shares have these.After the market, there was a big profit. The General Office of the Shanghai Municipal People's Government issued a notice on printing and distributing the Action Plan of Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027).

Judging from the market performance, the average growth rate of 41 key sector stocks since September 18 is close to 56%, far outperforming the performance of the broader market in the same period. Among them, two stocks of Xinxiangwei and SMIC doubled. Xinxiangwei's main business focuses on the research, development, design and sales of display chips, and is committed to providing complete display chip system solutions.Judging from the market performance, the average growth rate of 41 key sector stocks since September 18 is close to 56%, far outperforming the performance of the broader market in the same period. Among them, two stocks of Xinxiangwei and SMIC doubled. Xinxiangwei's main business focuses on the research, development, design and sales of display chips, and is committed to providing complete display chip system solutions.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.